Nirsevimab

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.

The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given). It was developed by AstraZeneca and Sanofi. Nirsevimab was approved for medical use in both the European Union and the United Kingdom in November 2022, in Canada in April 2023, and in the United States in July 2023.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378624083 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

20 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.